Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.61 |
| ▸ | MMP13 | P45452 | 11/20 | 0.48 |
| ▸ | MMP14 | P50281 | 5/20 | 0.48 |
| ▸ | MMP12 | P39900 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL941795 | 0.93 | GRM5 (0.55) | GRM5MMP13MMP14MMP12 | |
| SCHEMBL2292206 | 0.84 | MMP13 (0.44) | MMP13MMP14MMP12 | |
| SCHEMBL4009583 | 0.84 | MMP13 (0.44) | MMP13MMP14MMP12 | |
| SCHEMBL3933308 | 0.83 | MMP13 (0.45) | GRM5MMP13MMP14MMP12 | |
| SCHEMBL2289321 | 0.81 | MMP13 (0.43) | MMP13MMP14MMP12 | |
| SCHEMBL5241113 | 0.81 | MMP13 (0.43) | MMP13MMP14MMP12 | |
| SCHEMBL5103259 | 0.81 | MMP13 (0.48) | MMP13MMP14MMP12 | |
| SCHEMBL5103261 | 0.81 | MMP13 (0.48) | MMP13MMP14MMP12 | |
| SCHEMBL8273858 | 0.81 | MMP13 (0.51) | MMP13MMP14MMP12 | |
| SCHEMBL6835855 | 0.81 | MMP13 (0.44) | MMP13MMP14MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989620-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-20100144771-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-7648992-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080004317-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | GRM5 3668/4885MMP13 12/4885MMP14 3/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | GRM5 3668/4885MMP13 12/4885MMP14 3/4885 |
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | GRM5 2437/4885MMP13 519/4885MMP14 2128/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | GRM5 3668/4885MMP13 12/4885MMP14 3/4885 |
| US-20080004317-A1 | Compounds | CYP1A2, CYP2D6, F12 | GRM5 3038/4885MMP13 4291/4885MMP14 4794/4885 |
| US-20100144771-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | GRM5 2364/4885MMP13 520/4885MMP14 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.